Fundraising Fox

Neurogastrx

Woburn, US · 4 known investors

neurogastrx.com ↗

Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options. It focuses on identifying and advancing drug candidates for GI conditions, with a stated focus on the United States.

BiotechHealthtech

Investors · 4

5AM VenturesBoston · $100K – $4M
OrbiMedNew York · $1M – $75M
venBio PartnersSan Francisco
Vivo CapitalPalo Alto · $10M – $50M

In the news

Neurogastrx rakes in $60m Series Bventurecapitaljournal.com · Aug 2021After pandemic delay and a South Korean deal, Boston-area biotech raises Series B with sights on IPOendpoints.news · Aug 2021Neurogastrx Secures $60 Million in Series B | citybizcitybiz.co · Aug 2021Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders - BioSpacebiospace.com · Aug 2021Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Conceptprnewswire.com · Jan 2018Neurogastrx Raises $45M in Series A Funding - FinSMEsfinsmes.com · Jan 2018

Frequently asked questions

What does Neurogastrx do?
Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options. It focuses on identifying and advancing drug candidates for GI conditions, with a stated focus on the United States.
Who are Neurogastrx's investors?
Neurogastrx's investors include 5AM Ventures, OrbiMed, venBio Partners, Vivo Capital.
Where is Neurogastrx headquartered?
Neurogastrx is headquartered in Woburn, US.